TG Therapeutics (NASDAQ:TGTX) Receives Buy Rating from HC Wainwright

TG Therapeutics (NASDAQ:TGTX – Get Rating)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $24.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 64.61% from the stock’s previous close. Several other […]

Related Keywords

United States ,America ,Yann Echelard ,Laurenceh Shaw ,Laurencen Charney ,Michael Sean Weiss ,Cantor Fitzgerald ,Securities Exchange Commission ,Tg Therapeutics Company Profile ,Hermes Inc ,Goldman Sachs Group ,Vanguard Group Inc ,Tg Therapeutics Inc ,Deerfield Management Companylp Series ,Get Rating ,Trading Down ,Director Yann Echelard ,Exchange Commission ,Director Laurence ,Street Corp ,Tg Therapeutics ,Nasdaq Tgtx ,Tgtx ,Medical ,Reiterated Rating ,Hc Wainwright ,